Filgotinib Phase 3 JIA Extension Trial, France Germany UK

A Phase 3 clinical trial extension study for filgotinib in juvenile idiopathic arthritis has been registered on ClinicalTrials.gov. The trial is being conducted across three European countries. Clinical trial registrations on ClinicalTrials.gov are mandatory for certain study types and provide public transparency into ongoing research. This entry documents the trial's location, phase, and study identifier.

Affected parties including clinical investigators, sponsors, and institutional review boards should note this trial registration for pharmacovigilance and competitive intelligence purposes. Sponsors and clinical sites in France, Germany, and the UK conducting JIA research may want to review eligibility criteria to identify potential patient overlap or competitive enrollment considerations.